|
US2021101926A1
|
|
Synthesis of glycoconjugate derivatives of a bile acid
|
|
CN111825737A
|
|
Purification of cholanic acid conjugates
|
|
US2019241585A1
|
|
Intermediates and process for the preparation of a crystalline form of a topical anti-inflammatory agent
|
|
WO2019020362A1
|
|
Synthesis of an azasugar and intermediates thereof
|
|
US2018327383A1
|
|
Process for the preparation of crystalline dexlansoprazole
|
|
US2018208542A1
|
|
Method for preparing selegiline base
|
|
US2018009753A1
|
|
Method for preparing an antifibrotic agent
|
|
US2019106455A1
|
|
Method for preparing a farnesoid X receptor agonist
|
|
WO2017037296A1
|
|
Stable adducts of 2-iodoxybenzoic acid
|
|
US2017036991A1
|
|
Isolation and purification of 6-aminocaproic acid
|
|
EP3112360A1
|
|
Process for the preparation of efinaconazole
|
|
EP3091007A1
|
|
Process for the preparation of piperidine compounds
|
|
EP3081555A1
|
|
Synthesis of an azasugar and the intermediates thereof
|
|
EP3023417A1
|
|
Process for the preparation of an antidepressant and the intermediates thereof
|
|
US2016015706A1
|
|
Crystalline forms of an antidepressant compound
|
|
US2016031796A1
|
|
Antimuscarinic compound having a low content of impurities
|
|
US2017101365A1
|
|
Azidoalkylamine salts and their use as intermediates
|
|
US2015126526A1
|
|
Co-crystal of an antidepressant compound
|
|
EP2865662A1
|
|
Process for the preparation of a thrombopoietin agonist
|
|
US2015099899A1
|
|
Process for the purification of 2-phenyl-2-methyl-propanoic acid derivatives
|
